Drugs giant AstraZeneca, hyperactive last week after the Food & Drug Administration approved its cholesterol-lowering drug Crestor for marketing in the US, collapsed 101p to 2459p. Goldman Sachs did the damage by raising concerns about what Exanta, its anti-clotting drug, might do to your liver.